AKT3
RAC-gamma serine/threonine-protein kinase
As of the edition of 20 October 2026, AKT3 (RAC-gamma serine/threonine-protein kinase, UniProt Q9Y243) has 13 drugs tested at it and 12 companies on the list, 6 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9Y243
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 2
- Disease areas
- Cancer; Skin and connective tissue; Urinary and reproductive; Blood and lymph; Pregnancy and women's health; Immune system; Hormones; Digestive system
- Registered trials of its drugs
- 203
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 3 |
| Went quiet | 1 |
| Stopped | 8 |
| Total | 13 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Capivasertib | Marketed | Phase 3 | Ends 2033 |
| Ipatasertib | Active | Phase 3 | none listed |
| MK-2206 | Stopped | Phase 2 | none listed |
| Afuresertib | Active | Phase 3 | none listed |
| Uprosertib | Stopped | Phase 2 | none listed |
| Miransertib | Active | Phase 2 | none listed |
| Triciribine phosphate | Stopped | Phase 2 | none listed |
| LY-2780301 | Stopped | Phase 2 | none listed |
| GSK-690693 | Stopped | Phase 1 | none listed |
| Pifusertib | Stopped | Phase 2 | none listed |
| Rupitasertib | Went quiet | Phase 1 | none listed |
| TAS0612 | Stopped | Phase 1 | none listed |
12 of 13 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 6 |
| Route B | 1 |
| Engaged | 5 |
| Total on the list | 12 |
| Company | Route |
|---|---|
| AstraZeneca | Route B |
| Novartis | Route A |
| Taiho | Route A |
The other 9 companies at AKT3
In the product12 companies in all; 9 are not named here, and no score is.
See the 12 companies at AKT3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.